U Gatzemeier

Summary

Country: Germany

Publications

  1. ncbi First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: a subgroup analysis of data from the FLEX phase 3 study
    Ulrich Gatzemeier
    Department of Thoracic Oncology, Hospital Grosshansdorf, Hamburg, Germany
    Lancet Oncol 12:30-7. 2011
  2. ncbi XM02, the first biosimilar G-CSF, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with small cell or non-small cell lung cancer receiving platinum-based chemotherapy
    Ulrich Gatzemeier
    Center of Pneumology and Thoracic Surgery, Department of Thoracic Surgery, Grosshansdorf, Germany
    J Thorac Oncol 4:736-40. 2009
  3. ncbi Gefitinib ("Iressa"): a new therapy for advanced non-small-cell lung cancer
    Martin Reck
    Department of Thoracic Oncology, Hospital Grosshansdorf, Woehrendamm 80, Grosshansdorf 22927, Germany
    Respir Med 99:298-307. 2005
  4. ncbi Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial
    Ulrich Gatzemeier
    Zentrum fur Pneumologie und Thoraxchirurgie, Krankenhaus D LVA, Germany
    J Clin Oncol 25:1545-52. 2007
  5. ncbi Indications for chemotherapy in stage IV non-small cell lung cancer
    U Gatzemeier
    Department of Thoracic Oncology, Hospital Grosshansdorf, Centre of Pneumology and Thoracic Surgery, Woehrendamm 80, D 22927, Grosshansdorf, Germany
    Lung Cancer 33:S109-13. 2001
  6. ncbi Tirapazamine-cisplatin: the synergy
    U Gatzemeier
    Department of Thoracic Oncology, Hospital Grosshansdorf, Hamburg, Germany
    Br J Cancer 77:15-7. 1998
  7. ncbi Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer
    U Gatzemeier
    Krankenhaus Grosshansdorf, Grosshansdorf, Germany
    Ann Oncol 15:19-27. 2004
  8. ncbi Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma
    C Manegold
    Heidelberg University Medical Center, Mannheim, Germany
    Ann Oncol 16:923-7. 2005
  9. ncbi Airway responsiveness to methacholine does not change during chemotherapy in patients with chronic bronchitis and bronchial carcinoma
    H Magnussen
    Krankenhaus Grosshansdorf, Zentrum fur Pneumologie und Thoraxchirurgie, Hamburg, FRG
    Am Rev Respir Dis 139:844-6. 1989
  10. ncbi A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer
    M Reck
    Department of Thoracic Oncology, Hospital Grosshansdorf, Grosshansdorf, Hamburg, Germany
    Ann Oncol 22:1374-81. 2011

Collaborators

Detail Information

Publications27

  1. ncbi First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: a subgroup analysis of data from the FLEX phase 3 study
    Ulrich Gatzemeier
    Department of Thoracic Oncology, Hospital Grosshansdorf, Hamburg, Germany
    Lancet Oncol 12:30-7. 2011
    ..The main cetuximab-related side-effect was acne-like rash. Here, we assessed the association of this acne-like rash with clinical benefit...
  2. ncbi XM02, the first biosimilar G-CSF, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with small cell or non-small cell lung cancer receiving platinum-based chemotherapy
    Ulrich Gatzemeier
    Center of Pneumology and Thoracic Surgery, Department of Thoracic Surgery, Grosshansdorf, Germany
    J Thorac Oncol 4:736-40. 2009
    ..The aim of the study was to show that a new granulocyte colony-stimulating factor, XM02, is as safe and effective as Neupogen in the treatment of chemotherapy-induced neutropenia in patients with small cell or non-small cell lung cancer...
  3. ncbi Gefitinib ("Iressa"): a new therapy for advanced non-small-cell lung cancer
    Martin Reck
    Department of Thoracic Oncology, Hospital Grosshansdorf, Woehrendamm 80, Grosshansdorf 22927, Germany
    Respir Med 99:298-307. 2005
    ..Now approved for the treatment of advanced NSCLC in over 25 countries, including Japan and the USA, gefitinib has demonstrated significant clinical benefit in a disease area with limited treatment options...
  4. ncbi Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial
    Ulrich Gatzemeier
    Zentrum fur Pneumologie und Thoraxchirurgie, Krankenhaus D LVA, Germany
    J Clin Oncol 25:1545-52. 2007
    ....
  5. ncbi Indications for chemotherapy in stage IV non-small cell lung cancer
    U Gatzemeier
    Department of Thoracic Oncology, Hospital Grosshansdorf, Centre of Pneumology and Thoracic Surgery, Woehrendamm 80, D 22927, Grosshansdorf, Germany
    Lung Cancer 33:S109-13. 2001
    ..Patients with adverse prognostic factors such as elderly or stage IV patients with a reduced performance status are preferably treated with single agents such as gemcitabine, paclitaxel or vinorelbine...
  6. ncbi Tirapazamine-cisplatin: the synergy
    U Gatzemeier
    Department of Thoracic Oncology, Hospital Grosshansdorf, Hamburg, Germany
    Br J Cancer 77:15-7. 1998
    ..The combination of tirapazamine and cisplatin appears to be safe and effective in the treatment of NSCLC...
  7. ncbi Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer
    U Gatzemeier
    Krankenhaus Grosshansdorf, Grosshansdorf, Germany
    Ann Oncol 15:19-27. 2004
    ..The present randomized phase II trial examined the effect of adding trastuzumab to a standard chemotherapeutic combination (gemcitabine-cisplatin) in patients with HER2-positive NSCLC...
  8. ncbi Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma
    C Manegold
    Heidelberg University Medical Center, Mannheim, Germany
    Ann Oncol 16:923-7. 2005
    ..Because post-study chemotherapy (PSC) may have influenced the outcome of the trial, we examined its use and association with survival...
  9. ncbi Airway responsiveness to methacholine does not change during chemotherapy in patients with chronic bronchitis and bronchial carcinoma
    H Magnussen
    Krankenhaus Grosshansdorf, Zentrum fur Pneumologie und Thoraxchirurgie, Hamburg, FRG
    Am Rev Respir Dis 139:844-6. 1989
    ..These data suggest that a significant chemotherapy-induced leukocyte depletion in the peripheral blood does not influence airway responsiveness in patients with chronic bronchitis and bronchial carcinoma...
  10. ncbi A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer
    M Reck
    Department of Thoracic Oncology, Hospital Grosshansdorf, Grosshansdorf, Hamburg, Germany
    Ann Oncol 22:1374-81. 2011
    ..To assess the efficacy, safety, tolerability and pharmacokinetics of BIBF 1120 in patients with stage IIIB/IV non-small-cell lung cancer (NSCLC)...
  11. ncbi Time course of exhaled hydrogen peroxide and nitric oxide during chemotherapy
    A R Wewel
    Hospital Grosshansdorf, Center for Pneumology and Thoracic Surgery, , D-22927 Grosshansdorf, Germany
    Eur Respir J 27:1033-9. 2006
    ..In contrast, the production of exhaled nitric oxide seems to be primarily associated with monocytes...
  12. ncbi Difficulties in carboplatin dosage due to different methods of serum creatinine determination
    G Groth
    Department of Thoracic Oncology, Hospital Grosshandsdorf, Woehrendamm 80, Grosshansdorf 229727, Germany
    Lung Cancer 38:97-8. 2002
  13. ncbi Randomized study of vinorelbine--gemcitabine versus vinorelbine--carboplatin in patients with advanced non-small cell lung cancer
    E H Tan
    National Cancer Centre, 11 Hospital Drive, Singapore 169610, Singapore
    Lung Cancer 49:233-40. 2005
    ..CONCLUSION: VG compared to VC resulted in a similar overall response rate, favourable median survival and a better toxicity profile. For non-cisplatin-based chemotherapy, VG is a useful alternative...
  14. ncbi Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer
    L Paz-Ares
    Hospital Universitario 12 de Octubre, Servicio de Oncologia Medica, Madrid 28041, Spain
    Br J Cancer 98:1608-13. 2008
    ..Paclitaxel poliglumex at a dose of 210 mg m(-2) resulted in increased neurotoxicity compared with docetaxel...
  15. ncbi [Chemotherapy of malignant pleural mesothelioma: have we made any progress?]
    M Reck
    Onkologischer Schwerpunkt, Krankenhaus Grosshansdorf
    Zentralbl Chir 133:238-42. 2008
    ....
  16. ncbi [Phase II-trial of tirapazamine in combination with cisplatin and gemcitabine in patients with advanced non-small-cell-lung-cancer (NSCLC)]
    M Reck
    Onkologischer Schwerpunkt, Krankenhaus Grosshansdorf, Grosshansdorf
    Pneumologie 58:845-9. 2004
    ..Treatment of advanced and metastatic NSCLC with TPZ in combination with Gemcitabine/Cisplatin was well feasible and showed results recording to currently published data. The results of a following phase III-trial are awaited...
  17. ncbi Ifosfamide, carboplatin and etoposide combined with 41.8 degrees C whole body hyperthermia for malignant pleural mesothelioma
    A Bakhshandeh
    Medical University of Lubeck, Ratzeburger Allee 160, 23538, Luebeck, Germany
    Lung Cancer 39:339-45. 2003
    ..One patient died due to sepsis. These promising results are consistent with continued clinical investigation; a phase III clinical trial with whole body hyperthermia as the independent variable has been initiated...
  18. ncbi [Chemotherapy of advanced non-small cell bronchial cancer with mitomycin C/ifosfamide versus mitomycin C/vindesine versus cisplatin/etoposide--a prospective randomized study]
    U Gatzemeier
    Pneumologisch-Onkologische Abteilung, Krankenhaus Grosshansdorf
    Pneumologie 44:258-60. 1990
    ..On the basis of these results and the-state of our knowledge to date, the conclusion may be drawn that cisplatin-containing combinations should no longer be employed in the chemotherapeutic treatment of non-small-cell cancers...
  19. ncbi [Carboplatin-Vepeside in the treatment of non-small cell bronchial cancers. A phase II study]
    M Heckmayr
    Pneumologisch-Onkologische Abt, Krankenhaus Grosshansdorf, , LVA Freie und Hansestadt Hamburg
    Pneumologie 44:588-9. 1990
    ..Neither alone nor in combination does carboplatin appear to show any nephrotoxicity or otoxicity, and its neurotoxic effect is only slight...
  20. ncbi [Chemotherapy of advanced non-small-cell and small-cell bronchial carcinoma with bendamustine--a phase II study]
    M Reck
    , Krankenhaus Grosshansdorf
    Pneumologie 52:570-3. 1998
    ..Because of the good toxicity profile a combination with other compounds might be feasible. In advanced NSCLC Bendamustin showed no activity...
  21. ncbi [Cisplatin-Vepeside versus Endoxan-Vepeside in the treatment of small cell bronchial cancer. A randomized study]
    M Heckmayr
    Pneumologisch-Onkologische Abteilung, Krankenhaus-Grosshansdorf
    Pneumologie 44:256-7. 1990
    ..With respect to duration of remission and survival duration, however, no significant differences were to be seen...
  22. ncbi Adenovirus-mediated wild-type p53 gene transfer in patients receiving chemotherapy for advanced non-small-cell lung cancer: results of a multicenter phase II study
    M Schuler
    Department of Medicine III, Johannes Gutenberg University, Mainz, Germany
    J Clin Oncol 19:1750-8. 2001
    ..CONCLUSION: Intratumoral adenoviral p53 gene therapy appears to provide no additional benefit in patients receiving an effective first-line chemotherapy for advanced NSCLC...
  23. ncbi [Recommendations on the therapy of bronchial carcinoma]
    M Thomas
    , Onkologie und Pneumologie, Medizinische Klinik A, , Germany
    Pneumologie 56:113-31. 2002
  24. ncbi Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial
    R Rosell
    Hospital Germans Trias i Pujol Hospital, Badalona, Spain
    Ann Oncol 13:1539-49. 2002
    ..Survival, toxicity and quality of life were also compared...
  25. ncbi GLOB-1: a prospective randomised clinical phase III trial comparing vinorelbine-cisplatin with vinorelbine-ifosfamide-cisplatin in metastatic non-small-cell lung cancer patients
    P J Souquet
    Centre Hospitalier Lyon Sud, France
    Ann Oncol 13:1853-61. 2002
    ..The standard doublet, vinorelbine-cisplatin, was compared with a triplet of vinorelbine-ifosfamide-cisplatin, in terms of survival, in patients with advanced non-small-cell lung cancer (NSCLC)...
  26. ncbi [Chemotherapy of small cell bronchial cancer with a combination of carboplatin, vincristine and etoposide]
    U Gatzemeier
    Pneumologisch-Onkologische Abteilung, Krankenhaus Grosshansdorf
    Pneumologie 44:584-5. 1990
    ..For a definitive assessment of its usefulness, it must be compared with other standard treatment regimens in prospective, randomized studies...
  27. ncbi Phase ii comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer
    J Von Pawel
    Asklepios Fachklinik, , Munich, Germany
    J Clin Oncol 19:1743-9. 2001
    ....